Obesity News and Research

Latest Obesity News and Research

Engineered lettuce may turn injectable GLP-1 therapies into oral pills

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, they have since also transformed the therapeutic landscape of obesity and weight management.

6 Mar 2026

Weekend lie-ins may boost insulin sensitivity, but too much may backfire

This study explores the relationship between sleep patterns and insulin sensitivity, emphasizing the impact of weekday sleep and weekend catch-up on metabolism.

6 Mar 2026

Drug combination shows greater weight loss while preserving muscle mass

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue.

5 Mar 2026

Tracking physiological stress during prolonged virtual soccer

Extended esports play can lead to mental fatigue, resulting in slower and less precise decision-making (diminished executive control) and a variety of physiological responses indicative of impaired sensorimotor or cognitive function.

5 Mar 2026

Using microwave frying to create heart-healthy production methods

Fried foods are popular with consumers, but their high fat content can contribute to health challenges like obesity and hypertension. If the food industry can offer lower-fat options of similar quality, people can more easily make health-conscious food choices.

5 Mar 2026

Mapping the year-one weight trajectory after stopping GLP-1s

A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain, on average, 60% of their lost weight – but beyond this, their weight regain plateaus, with individuals managing to keep off 25% of the weight lost to treatment, say researchers at the University of Cambridge.

4 Mar 2026

A sharp rise in "very short sleep" among US teens

Teenagers across the country are getting less sleep, a researcher from the University of Connecticut reports on March 2nd, 2026, in JAMA. And the problem appears to be societal.

4 Mar 2026

GLP-1 drugs may be effective at treating and preventing substance use disorders

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be effective at treating and preventing substance use disorders across all major addictive substances studied, suggesting these drugs target a common biological pathway underlying addiction.

4 Mar 2026

Why we keep craving food even when we are full

Research shows food cues activate brain reward signals, leading to eating without hunger, shedding light on obesity and appetite regulation mechanisms.

4 Mar 2026

Ultra-processed foods linked to behavioral issues in preschoolers

A team led by researchers at the University of Toronto has found an association between ultra-processed foods in early childhood, and behavioral and emotional development.

3 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

Puberty reshapes DNA to worsen or reverse insulin resistance

This study uncovers epigenetic changes during puberty that correlate with insulin resistance, offering insights into childhood obesity and metabolic risk.

3 Mar 2026

Global breast cancer burden rising fastest in low-income countries

Despite recent advancements in breast cancer treatments, new breast cancer cases in women are predicted to rise by a third globally from 2.3 million in 2023 to more than 3.5 million in 2050.

2 Mar 2026

Weight-loss drugs may reduce heart damage after heart attack

Weight-loss (GLP-1 mimicking) drugs may help prevent further tissue damage following a heart attack, significantly reducing the risk of further life-threatening complications that affect up to half of all patients, according to a new study led by the University of Bristol and University College London.

2 Mar 2026

The surprising neurological benefits of GLP-1s

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

2 Mar 2026

Decoding the brain’s love for tempting snacks

Research from the University of East Anglia (UEA) may finally explain why we still reach for the biscuit tin, even when we're full.

1 Mar 2026

Greater food variety at buffets may lead to overeating

At Super Bowl parties, weddings, Independence Day cookouts and Thanksgiving dinners, people celebrate with large spreads of food.

27 Feb 2026

How physical strength and self-belief grow together in teens

Physical fitness and psychological resilience develop side by side during adolescence, a life stage that lays the foundation for adult health. Cardiorespiratory endurance, muscular strength, and agility are well-known predictors of cardiometabolic health, while self-efficacy, defined as the belief in one's ability to overcome challenges, shapes motivation, persistence, and coping strategies.

26 Feb 2026

New review explains how circular RNAs could unlock fat browning therapies

A Cell Death & Disease review synthesizes preclinical evidence that circular RNAs regulate adipose browning and metabolic pathways through microRNA interactions, protein binding, and organelle-linked stress mechanisms. It highlights their biomarker and therapeutic potential in obesity and type 2 diabetes while underscoring key translational challenges, including delivery specificity and human validation.

26 Feb 2026

Heavy alcohol intake is associated with dangerous belly fat accumulation, large UK study shows

In a large UK population cohort, higher weekly alcohol consumption was dose-dependently associated with greater visceral fat mass measured by DXA, independent of total body fat. Heavy drinkers showed over 10% higher proportional visceral fat compared with lower consumption groups, a pattern linked to increased cardiometabolic risk.

26 Feb 2026